Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Covington
Express Scripts
Colorcon
Johnson and Johnson
Accenture
Harvard Business School
Daiichi Sankyo
Queensland Health
Julphar
Deloitte

Generated: October 18, 2017

DrugPatentWatch Database Preview

Details for Patent: 7,544,364

« Back to Dashboard

Which drugs does patent 7,544,364 protect, and when does it expire?


Patent 7,544,364 protects VIBATIV and is included in one NDA.

This patent has ninety-one patent family members in thirty-four countries.

Summary for Patent: 7,544,364

Title:Pharmaceutical compositions containing a glycopeptide antibiotic and a cyclodextrin
Abstract:Disclosed are pharmaceutical compositions containing a cyclodextrin and a therapeutically effective amount of a glycopeptide antibiotic or a salt thereof. Also disclosed are methods of treating a bacterial disease in a mammal by administering such pharmaceutical compositions.
Inventor(s): Judice; J. Kevin (El Granada, CA), Shaw; Jeng-Pyng (Saratoga, CA), Mu; YongQi (Los Altos, CA), Conner; Michael W. (Half Moon Bay, CA), Pace; John L. (San Anselmo, CA)
Assignee: Theravance, Inc. (South San Francisco, CA)
Application Number:11/410,597
Patent Claim Types:
see list of patent claims
Composition; Compound;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Theravance Biopharma
VIBATIV
telavancin hydrochloride
POWDER;IV (INFUSION)022110-001Sep 11, 2009DISCNYesNo► Subscribe► SubscribeY
Theravance Biopharma
VIBATIV
telavancin hydrochloride
POWDER;IV (INFUSION)022110-002Sep 11, 2009RXYesYes► Subscribe► SubscribeY
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Patent: 7,544,364

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,831,150 Reductive alkylation process► Subscribe
7,208,471Glycopeptide phosphonate derivatives► Subscribe
7,074,760Polyacid glycopeptide derivatives► Subscribe
7,026,288Pharmaceutical compositions containing a glycopeptide antibiotic and a cyclodextrin► Subscribe
7,265,086Glycopeptide carboxy-saccharide derivatives► Subscribe
6,620,781 Glycopeptide carboxy-saccharide derivatives► Subscribe
6,872,804 Glycopeptide disulfide and thioester derivatives► Subscribe
8,158,580Pharmaceutical compositions containing a glycopeptide antibiotic and a cyclodextrin► Subscribe
7,351,691Glycopeptide phosphonate derivatives► Subscribe
7,067,483Pharmaceutical compositions containing a gycopeptide antibiotic and a cyclodextrin► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 7,544,364

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Argentina035333► Subscribe
Austria337334► Subscribe
Austria388960► Subscribe
Austria402951► Subscribe
Austria416791► Subscribe
Australia2001261107► Subscribe
Australia5746401► Subscribe
Australia5929801► Subscribe
Australia5930201► Subscribe
Australia5930301► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Chubb
QuintilesIMS
Citi
Healthtrust
UBS
US Army
McKinsey
Daiichi Sankyo
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot